Global Information
회사소개 | 문의 | 위시리스트

페스트 : 파이프라인 리뷰

Plague - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 245959
페이지 정보 영문 64 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


페스트 : 파이프라인 리뷰 Plague - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 64 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

페스트는 페스트균이라는 세균에 의해 일어나는 감염증입니다. 이 세균은 주로 쥐나 그에 기생하는 벼룩으로부터 발견됩니다. 인간이나 다른 동물은 쥐와의 접촉과 벼룩에 물려서 페스트에 감염됩니다. 이전에 페스트는 문명 전체를 붕괴시킨 적도 있었습니다. 현재는 생활수준 개선과 항생물질의 발전에 의해 페스트는 일반적인 질환은 아닙니다. 페스트의 일반적 증상으로 사타구니, 겨드랑이, 경부 등에 횡현(림프절이 부어올라 통증을 느끼는 부위)가 발생합니다. 페스트 중에서도 특히 드물고 심각한 증상의 경우에는 폐에 침범되어 사람간에 감염됩니다.

세계 각국의 페스트(Plague) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 각 임상 단계별 제품 목록, 주요 기업 개요, 주요 치료제 개요(제품 개요, 작용기서, 연구개발(R&D) 진전 상황), 최신 업계 동향 등의 조사 결과를 전해드립니다.

서론

  • 분석 범위

페스트 개요

치료제 개발

  • 페스트용 파이프라인 제품 : 개요
  • 페스트용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 페스트 치료제

대학/연구기관에서 연구중인 페스트 치료제

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

페스트 치료제 : 개발중인 제품 목록(기업별)

페스트 치료제 : 연구중인 제품 목록(대학/연구기관별)

페스트 치료제 개발에 참여하고 있는 기업

  • Aradigm Corporation
  • Grifols, S.A.
  • iBio, Inc.
  • Mucosis B.V.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.

페스트 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별
  • 치료 카테고리별

치료제 개요

  • anthrax + plague vaccine
  • ARD-3100
  • ciprofloxacin hydrochloride
  • plague vaccine
  • pneumonic plaque vaccine
  • Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague
  • TP-271
  • Yersinia pestis vaccine

페스트 치료제 : 최신 치료제 개요

페스트 치료제 : 개발이 휴지 상태인 제품

페스트 치료제 : 개발이 중지된 제품

페스트 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

KSM 15.10.14

List of Tables

  • Number of Products under Development for Plague, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Plague - Pipeline by Achaogen Inc, H1 2019
  • Plague - Pipeline by Aradigm Corp, H1 2019
  • Plague - Pipeline by Greffex Inc, H1 2019
  • Plague - Pipeline by iBio Inc, H1 2019
  • Plague - Pipeline by Prokarium Ltd, H1 2019
  • Plague - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Plague - Dormant Projects, H1 2019
  • Plague - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Plague, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2019, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plague - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plague - Overview
  • Plague - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Plague - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Plague - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Aradigm Corp
    • Greffex Inc
    • iBio Inc
    • Prokarium Ltd
    • Tetraphase Pharmaceuticals Inc
  • Plague - Drug Profiles
    • (anthrax + plague) (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anthrax + plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GreAnPla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GrePla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISAS-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumonic plaque vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VypVaxDuo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plague - Dormant Projects
  • Plague - Discontinued Products
  • Plague - Product Development Milestones
    • Featured News & Press Releases
      • Mar 08, 2017: DynPorts clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation
      • Feb 14, 2013: BioDiem Extends Cooperative Agreement with USAMRIID
      • Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development
      • Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial
      • May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague
      • Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q
 
BCC Research